Lipocine Inc.LPCNNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
27.69%
↑ 301% above average
Average (39q)
-13.76%
Historical baseline
Range
High:132.14%
Low:-100.00%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 27.69% |
| Q2 2025 | 99.77% |
| Q1 2025 | -1.05% |
| Q4 2024 | -32.32% |
| Q3 2024 | 0.00% |
| Q2 2024 | -100.00% |
| Q1 2024 | 0.00% |
| Q4 2023 | -100.00% |
| Q3 2023 | 0.00% |
| Q2 2023 | -100.00% |
| Q1 2023 | 0.00% |
| Q4 2022 | -100.00% |
| Q3 2022 | 0.00% |
| Q2 2022 | -100.00% |
| Q1 2022 | 0.00% |
| Q4 2021 | 0.00% |
| Q3 2021 | 0.00% |
| Q2 2021 | -100.00% |
| Q1 2021 | 0.00% |
| Q4 2020 | 0.00% |
| Q3 2020 | 0.00% |
| Q2 2020 | -100.00% |
| Q1 2020 | 36.41% |
| Q4 2019 | 7.47% |
| Q3 2019 | -12.77% |
| Q2 2019 | 0.73% |
| Q1 2019 | -10.64% |
| Q4 2018 | 53.34% |
| Q3 2018 | -4.01% |
| Q2 2018 | 7.61% |
| Q1 2018 | -22.05% |
| Q4 2017 | -13.65% |
| Q3 2017 | -50.17% |
| Q2 2017 | 33.18% |
| Q1 2017 | 132.14% |
| Q4 2016 | -11.83% |
| Q3 2016 | -41.33% |
| Q2 2016 | -3.95% |
| Q1 2016 | -3.34% |
| Q4 2015 | -41.58% |